
Claims

1. The compound of general formula (I)






wherein

ring A is a cycloalkyl or heterocyclyl group; and

in B-Y, Y is -O-, -C(O)-, -CH_2-, -NH-, -C_{1-4}alkyl-N(R^{18})- or bond and ring B is an optionally substituted heteroaryl, aryl or heterocyclyl group; or

B-Y- jointly represents -N(C_{1-4}alkyl)$_2$, C(O)OC_{1-4}alkyl, C_{1-4}alkyl optionally substituted with halogen, C_{1-4}alkoxy group or halogen;

or B-Y-A- jointly represents a 3*H*-spiro[2-benzofuran-1,4'-piperidin-1'-yl]; or

 group; or  group; or  group;

R^1 is a hydrogen, halogen, C_{1-4}alkyl, C_{1-4}alkoxy, CF_3 or CN;

R^2 is a hydrogen or C_{1-4}alkyl group;

R^3 is a NR^4R^5, OR^6 group or halogen;

or R^2 and R^3 jointly represent -O-(CH$_2$)$_m$-O-, oxo or =N-OH group;

R^4 and R^5 is independently a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, cycloalkyl, optionally substituted aryl or NR^8R^9 group; Cy^1; C(O)R^7; -S(O_2)R^{10} or C_{2-4}alkynyl group;

or R^4 and R^5 taken together with the N to which they are attached form a heterocycle;

R^6 is a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, Cy^2, C_{1-4}alkoxy, -S(O)$_2$-C_{1-4}alkyl or $NR^{11}R^{12}$ group; C(O)R^{13}; Si(CH$_3$)$_2$-*t*-butyl or C_{2-4}alkynyl group;

R^7 is a C_{1-4}alkyl optionally substituted with OH, CN, halogen, Cy^3 or $NR^{11}R^{12}$ group; C_{1-4}alkoxy, C_{2-4}alkenyl, Cy^3 or N(C_{1-4}alkyl)$_2$ group;

R^8 and R^9 is independently a hydrogen, C_{1-4}alkyl or C(O)OR^{21} group;

R^{10} is a C_{1-4}alkyl, OH or $NR^{14}R^{15}$ group;

R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;

or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;

R^{13} is a C_{1-4}alkyl optionally substituted with CN or $NR^{19}R^{20}$ group; Cy^3 or $NR^{16}R^{17}$ group;

R^{14} and R^{15} is independently a hydrogen or C_{1-4}alkyl group;

R^{16} and R^{17} is independently a hydrogen, C_{1-4}alkyl, or optionally substituted aryl group;

or R^{16} and R^{17} taken together with the N to which they are attached form a heterocycle;

R^{18} and R^{21} is a hydrogen or C_{1-4}alkyl group;

R^{19} and R^{20} is independently a hydrogen or C_{1-4}alkyl group;

Cy^1 is an optionally substituted cycloalkyl, heterocyclyl or heteroaryl group;

Cy^2 is an optionally substituted aryl or cycloalkyl group;

Cy^3 is an optinally substituted aryl, cycloalkyl, heterocyclyl or heteroaryl group;

X is a C_{1-4}alkyl, aryl or heteroaryl group;

Z is a C_{1-4}alkyl group;

m is 2, 3, 4 or 5

and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof.




2. The compound according to claim 1, wherein R^1 is a hydrogen, fluorine, chlorine, bromine, methyl, methoxy, CF_3 or CN.

3. The compound according to any of claims 1 to 2, wherein

ring A is a 3- to 6-membered saturated carbocyclic group or a 4- to 7-membered saturated heterocycle containing 1 or 2 N;

ring B is an optionally substituted 6- or 5-membered mono-heteroaryl group, 6- to 10-membered aromatic carbocycle, or 4- to 7-membered saturated, monocyclic, bicyclic, fused and/or bridged heterocycle containing 1, 2 or 3 heteroatoms selected from O, S or N;

or B-Y-A- jointly represents a 3*H*-spiro[2-benzofuran-1,4'-piperidin-1'-yl]; or


group; or

group; or

group; X is isopropyl group;

Z is methyl group.

4. The compound according to any of claims 1 to 3, wherein ring A is a 4- to 6-membered saturated carbocyclic group or a 4- to 7-membered saturated heterocycle containing 1 or 2

N attached via a ring nitrogen to Y or to the triazole ring of the 5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine core.

5. The compound according to any of claims 1 to 4, wherein ring A is cyclohexyl, Y is -O-, ring B is pyridin-2-yl and R^1 is chlorine.

6. The compound according to any of claims 1 to 5, wherein
R^2 is a hydrogen or C_{1-4}alkyl group;
R^3 is a NR^4R^5 group;
R^4 and R^5 is independently a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, cycloalkyl, optionally substituted aryl or NR^8R^9 group; Cy^1; $C(O)R^7$; $-S(O_2)R^{10}$ or C_{2-4}alkynyl group;
or R^4 and R^5 taken together with the N to which they are attached form a heterocycle;
R^7 is a C_{1-4}alkyl optionally substituted with OH, CN, halogen, Cy^3 or $NR^{11}R^{12}$ group; C_{1-4}alkoxy, C_{2-4}alkenyl, Cy^3 or $N(C_{1-4}alkyl)_2$ group;
R^8 and R^9 is independently hydrogen, C_{1-4}alkyl or $C(O)OR^{21}$ group;
R^{10} is a C_{1-4}alkyl, OH or $NR^{14}R^{15}$ group;
R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;
or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;
R^{14} and R^{15} is independently a hydrogen or C_{1-4}alkyl group;
R^{21} is a hydrogen or C_{1-4}alkyl group;
Cy^1 is an optionally substituted cycloalkyl, heterocyclyl or heteroaryl group;
Cy^3 is an optionally substituted aryl, cycloalkyl, heterocyclyl or heteroaryl group.

7. The compound according to claim 6, wherein R^2 is a hydrogen and R^4 and R^5 is independently a hydrogen or a C_{1-4}alkyl group.

8. The compound according to any of claims 1 to 5, wherein
R^2 is a hydrogen or C_{1-4}alkyl group;
R^3 is an OR^6 group;
R^6 is a hydrogen; C_{1-4}alkyl group optionally substituted with OH, halogen, Cy^2, C_{1-4}alkoxy, $-S(O)_2-C_{1-4}$alkyl or $NR^{11}R^{12}$ group; $C(O)R^{13}$, $Si(CH_3)_2$-*t*-butyl or C_{2-4}alkynyl group;
R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;
or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;
R^{13} is a C_{1-4}alkyl group optionally substituted with CN or $NR^{19}R^{20}$ group; Cy^3 or $NR^{16}R^{17}$ group;

R^{16} and R^{17} is independently a hydrogen, C_{1-4}alkyl or optionally substituted aryl group; or R^{16} and R^{17} taken together with the N to which they are attached form a heterocycle;
R^{19} and R^{20} is independently a hydrogen or C_{1-4}alkyl group;
Cy^2 is an optionally substituted aryl or cycloalkyl group.

9. The compound according to claim 8, wherein R^2 is a hydrogen and R^6 is a hydrogen or a C_{1-4}alkyl group.

10. The compound according to any of claims 6 to 9, wherein the absolute configuration of the carbon at position 5 in the 5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine core is (*S*) or (*R*).

11. The compound according to any of claims 1 to 5, wherein R^2 and R^3 jointly represent -O-$(CH_2)_m$-O-, oxo or =N-OH group, m is 2, 3, 4 or 5.

12. The compound according to claim 11, wherein R^2 and R^3 jointly represent -O-$(CH_2)_m$-O- and m is 2.

13. The compound according to any of claims 1 to 12, wherein the compound is selected from the group consisting of:

tert-butyl [8-chloro-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl] carbamate,

8-chloro-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-[8-chloro-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl]acetamide,

N-(8-chloro-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl)-2-methylpropanamide,

tert-butyl {8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*]benzazepine-5-yl}carbamate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

(2*S*)-2-amino-*N*-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-phenylacetamide,

(2*R*)-2-amino-*N*-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-phenylacetamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxyacetamide,

3-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-1,1-dimethylurea,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^2,N^2-dimethylglycinamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}methanesulfonamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*-methylmethanensulfonamide,

N'-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*,*N*-dimethylsulfamide,

8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*R*)-8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-cyclobutyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(oxetan-3-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(4,4-difluorcyclohexyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine hydrochloride,

8-methoxy-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

tert-butyl {1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine hydrochloride,

N,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methyl-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-chloro-1-(3,3-difluorocyclobutyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-(4,4-difluorocyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-*N*-(propan-2-yl)-1-[*trans*-4-(trifuoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8'-(trifluoromethyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-(cyclopropylmethoxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-{[*tert*-butyl(dimethyl)silyl]oxy}-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-(cyclopropylmethoxy)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

2-({8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}oxy)-*N*,*N*-dimethylethanamine,

8'-chloro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-bromo-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepine],

1'-[t*rans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepin]-8'-carbonitrile,

(5*S*)-8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-*N*-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

8'-chloro-1'-[*trans*-4-(pyridin-2-ylmethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine]-1'-yl)cyclohexyl](pyrrolidin-1-yl)methanone,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(cis)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-3-methyl-1-oxa-3-azaspiro[4.5]decan-2-one,

8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(*trans*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-3-methyl-1-oxa-3-azaspiro[4.5]decan-2-one,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*-methylmethanesulfonamide,

(5*S*)-8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8'-chloro-1'-[1-(pyrimidin-2-yl)azetidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4-fluorobenzamide,

8'-bromo-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

5-(propan-2-ylamino)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-8-carbonitrile trifluoroacetate,

(5*S*)-8-chloro-*N*-(4-fluorobenzyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine]-8'-carbonitrile,

[*trans*-4-(8'-bromo-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepin]-1'-yl)cyclohexyl](piperidin-1-yl)methanone,

methyl *trans*-4-(8-bromo-5-oxo-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexane carboxilate,

8-bromo-1-[*trans*-4-(piperidin-1-ylcarbonyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8'-chloro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1'-[*trans*-4-(piperidin-1-ylcarbonyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-8'-carbonitrile,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

[*trans*-4-(8-bromo-5-hydroxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl](piperidin-1-yl)methanone,

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

1'-(1,4'-bipiperidin-1'-yl)-8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

tert-butyl [1-(1,4'-bipiperidin-1'-yl)-8-chloro-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl]carbamate,

8'-fluoro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(4-fluorobenzyl)-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}prop-2-enamide,

(5*R*)-8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*R*)-8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*R*)-8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

(5*S*)-8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-(propan-2-yloxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxepane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)cyclohexyl](morpholin-4-yl)methanone

5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

tert-butyl {8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*r*,8*r*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

(5*r*,8*r*)-8-(8-chloro-5-hydroxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5-(pyrrolidin-1-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylpropanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclopropanecarboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylpropanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclobutanecarboxamide,

(5*S*)-8-chloro-5-(morpholin-4-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylpropanamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylpropanamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclobutanecarboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclopropanecarboxamide,

(5*S*)-8-chloro-5-(piperidin-1-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-*N*-(butan-2-yl)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*s*,8*s*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

8-chloro-5-methoxy-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-ethoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-*N*-(propan-2-yl)-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

2-({8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}oxy)ethanol,

(5*S*)-8-chloro-*N*,*N*-diethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-*N*-methyl-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

tert-butyl {8-chloro-1-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

tert-butyl 4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)piperidine-1-carboxylate,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-D-valinamide,

tert-butyl {1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

tert-butyl {8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-fluoro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}tetrahydro-2*H*-pyran-4-carboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylbutanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^{β},N^{β}-dimethyl-β-alaninamide,

(5*S*)-8-chloro-*N*-cyclopentyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8'-chloro-1'-[4-(pyridin-2-yloxy)piperidin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylbutanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxy-2-methylpropanamide,

(5*S*)-8-chloro-*N*-ethyl-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*S*)-8-chloro-*N*-(2-methylpropyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[*trans*-4-(morpholin-4-yl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine] hydrochloride,

8-chloro-*N*,*N*-dimethyl-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(2,2-dimethylpropyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

[*trans*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl](4-methylpiperazin-1-yl)methanone,

(5*R*)-8-chloro-5-(morpholin-4-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxy-2-methylpropanamide,

8-chloro-5-methoxy-1-[1-(tetrahydro-2*H*-pyran-4-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[4-(pyridin-2-yl)piperazin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-1-[4-(3-chloropyridin-2-yl)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5-(pyrrolidin-1-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-{1-[(3*S*)-tetrahydrofuran-3-yl]piperidin-4-yl}-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-{1-[(3*R*)-tetrahydrofuran-3-yl]piperidin-4-yl}-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^{β},N^{β}-dimethyl-β-alaninamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}tetrahydro-2*H*-pyran-4-carboxamide,

8-chloro-1-[4-(pyridin-2-yloxy)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-5-methoxy-1-[*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-cyanoacetamide,

[3-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)pyrrolidin-1-yl](pyridin-3-yl)methanone,

8'-chloro-1'-{1-[(3*R*)-tetrahydrofuran-3-yl]piperidin-4-yl}-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

[3-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)pyrrolidin-1-yl](pyridin-2-yl)methanone,

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*,*N*-dimethylcyclohexanamine,

8-chloro-5-methoxy-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)cyclohexyl]pyridin-2-amine,

N'-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*,*N*-dimethylethane-1,2-diamine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl acetate,

2-({(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}amino)ethanol,

8-chloro-5-methoxy-1-[4-(pyridin-2-yloxy)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-(*trans*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(cyclopropylmethyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-1-methylpiperidine-4-carboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2,2-trifluoroacetamide,

8-chloro-5-(2-methoxyethoxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-(4-methoxy-4-methylcyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-(*trans*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-[2-(methylsulfonyl)ethoxy]-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-*N*-hydroxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-imine,

(5*S*)-8-chloro-*N*-methyl-*N*-(prop-2-yn-1-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3,3-difluorocyclobutanecarboxamide,

8-chloro-5-(prop-2-yn-1-yloxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl 4,4-difluorocyclohexanecarboxylate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl 3,3-difluorocyclobutanecarboxylate,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4,4-difluorocyclohexanecarboxamide,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl cyanoacetate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl *N*,*N*-dimethylglycinate,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2,2-trifluoroacetamide,

1-[*cis*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl]pyrrolidin-2-one,

1-[*trans*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl]pyrrolidin-2-one,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3,3-difluorocyclobutanecarboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4,4-difluorocyclohexanecarboxamide,

8-chloro-5-methoxy-1-[*cis*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[*trans*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-*N*-(2,2,2-trifluoroethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3-methyloxetane-3-carboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3-methyloxetane-3-carboxamide,

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*-(4-methoxybenzyl)cyclohexanamine,

tert-butyl [2-({(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}amino)ethyl]carbamate,

8'-chloro-1'-(*trans*-4-ethoxy-4-ethylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*-(4-methoxybenzyl)-*N*-methylcyclohexanamine,

8'-chloro-1'-[1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[4-(pyridin-2-yl)piperazin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-(*trans*-4-ethyl-4-methoxycyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-(*trans*-4-ethoxy-4-methylcyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[*trans*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[*cis*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-ethyl-4-methoxycyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethyl-4-methoxycyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-methoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-methoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(*trans*-4-ethoxy-4-ethylcyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-(*trans*-4-ethoxy-4-ethylcyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[(3*R*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[(3*R*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[(3*R*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[(3*S*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[(3*R*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[(3*S*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[(3*S*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine] and

8-chloro-5-methoxy-1-[(3*S*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine.

14. A pharmaceutical composition comprising therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 13 as active substance and a pharmaceutically acceptable excipient.

15. A combinational composition comprising therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 13 and one or more other active substances selected from the group consisting of psycholeptics, psychoanaleptics, antihypertensives, spasmolytics, antiepileptics or other agents.

16. Use of the composition of any of claims 14 to 15 in the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders

and/or irritability, behavioural hyperactivity disorders, cognitive disorders and other neuropsychiatric disorders.

17. A process for the preparation of a pharmaceutical composition having V1a receptor antagonist activity comprising a therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 13 as active substance with pharmaceutically acceptable excipients.

18. Use of the compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 13 in the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders and other neuropsychiatric disorders.

19. Use of the compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 13 and one or more other active substances selected from the group consisting of psycholeptics, psychoanaleptics, antihypertensives, spasmolytics, antiepileptics or other agents in the manufacture of a medicament for the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression,

aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders and other neuropsychiatric disorders.

20. The compound selected from the group consisting of

tert-butyl (7-chloro-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

tert-butyl-(7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

tert-butyl-(7-chloro-2-thioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

tert-butyl-(7-bromo-2-thioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

tert-butyl-(7-chloro-2-(methylsulfanyl)-4,5-dihydro-3*H*-1-benzazepin-4-yl)carbamate,

7-chloro-1,5-dihydrospiro[1-benzazepine-4,2'-[1,3]dioxolane]-2(3*H*)-one,

7-bromo-1,5-dihydrospiro[1-benzazepine-4,2'-[1,3]dioxolane]-2(3H)-one,

4-{[*tert*-butyl(dimethyl)silyl]oxy}-7-chloro-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-one,

4-{[*tert*-butyl(dimethyl)silyl]oxy}-7-chloro-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-thione,

7-chloro-4-methoxy-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-one and

7-chloro-4-methoxy-1,3,4,5-tetrahydro-2*H*-1-benzazepine-2-thione.